In a period when trust, standards and transparency are essential to the development of the modern pharmaceutical industry, “Replek” is celebrating another significant anniversary. The company marks 10 years since launching its own manufacturing and development of medical cannabis-based products, becoming a pioneer in the domestic market in 2016, as well as one of the first regional players.
After a decade, Replek remains the only company in the region that bases the development, manufacturing and quality consistency of medical cannabis products on the strictest pharmaceutical standards and many years of expertise in pharmaceutical manufacturing. This approach ensures product safety, the highest quality standards and consistent product standardisation, particularly important for products derived from plant-based raw materials.
Ahead of this anniversary, a significant success was achieved – first export of medical cannabis-based products from “Replek” to the strict markets of the European Union. Entering on such a demanding market confirms the quality of the portfolio in this pharmaceutical segment, which “Replek” has been dedicatedly developing over the past 10 years.
“When we started with this pharmaceutical segment 10 years ago, the domestic market responded with scepticism. We were pioneers in this field, both in Macedonian and across the region. We chose to remain committed and work persistently towards realising this vision, and today we can confidently say that our decision was the right one, as demonstrated by our successful export to the European Union market. This product category offers significant growth potential, as the global medical cannabis market continues to expand rapidly, while also presenting substantial opportunities for the national economy, said Dushan Pecovski, CEO of “Replek”.
In order to provide accurate, verified and scientifically based information to all stakeholders, “Replek” established the KA-Information Centre in November last year, dedicated to providing information about products based on medical cannabis. The Centre is the first of its kind in the country and was established as a subsidiary of “Replek”, serving as the company’s platform that enables transparent and responsible communication on all issues related to the use of these products. The KA-Information Centre plays an important role in overcoming stereotypes related to medical cannabis and serves as the trusted point between the company, consumers and the healthcare professionals.
Since launching the production of medical cannabis products, a decade ago, it has managed the process systematically and responsibly, ensuring strong manufacturing and control standards. The manufacturing process of “Replek” is based on advanced supercritical CO₂ extraction and technology that enables high selectivity, reproducibility and stability of the extracts. Industrial equipment from renowned European manufacturers is used through the production process, while the validated technology ensures greater efficiency and better yield from raw materials, with consistent quality in every batch. The foundations of this success are continuous investments in advanced technologies, as well as the top expertise of the company’s professional team.
“Replek’s portfolio in this segment includes three groups of products, namely CBD oils, cannabis-based cosmetics, as well as products with CBD and THC intended as adjunctive therapy for serious medical conditions, always in accordance with applicable regulatory requirements. With its ten years of experience, proven quality, as well as exports to the European Union market, “Replek” today seriously positions the country on the map of the modern and responsible medical cannabis pharmaceutical industry.